with undetected stones were involved. All patients underwent kidney ultrasonography and X-ray examination, and body mass index (BMI) was calculated. Serum creatinine, parathyroid hormone, calcium, magnesium, anorganic phosphate, uric acid and urine creatinine, albumin, α 1 -microglobulin, sulphate, oxalate, citrate and fetuin-A (ELISA) were determined. RESULTSThe patients with urolithiasis had lower urine fetuin-A levels (median 4.9 vs 0.77 mg/day; P < 0.01) and citraturia levels (1.7 vs 5.1 mmol/day; P = 0.02); and higher calciuria (6.5 vs 5.2 mmol/day) and oxaluria (0.47 vs 0.25; P = 0.04). Patients with fetuin-A levels in the lowest quartile had an odds ratio of 36 compared with individuals in the highest quartile. The sensitivity of the urine fetuin-A level for urolithiasis was 97.4% and specificity was 100% (area under the curve 0.99; 95% confidence interval 0.94-1.0) using a urine fetuin-A threshold of ≤ 2.1 mg/day. Values of urine fetuin-A did not correlate with gender, age or BMI. CONCLUSIONSOur study indicates, for the first time, that patients with documented urolithiasis had lower fetuin-A concentrations independent of other conventional promotors and inhibitors of urine crystallization.
Background: N1,N12-diacetylspermine, a diacetylpolyamine which was recently identified in urine, appeared to be a useful tumor marker for a number of cancers. No valid data on urine diacetylspermine concentration in patients with urinary bladder cancer exist.Aim: Evaluation of urine N1,N12-diacetylspermine concentrations in individuals with urinary bladder cancer. Methods: Urine samples were used from 36 patients with urothelial tumors of the urinary bladder and from 30 patients with benign urological diseases. Urine was collected before cystoscopy. Enzyme-linked immunoabsorbent assays (ELISA) were performed for diacetylspermine from urine.Results: Urine diacetylspermine did not differentiate in individuals with urinary bladder cancer from controls (medians 171.5 vs 143.8, p = 0.64). Its efficacy for urinary bladder cancer detection was not shown.Conclusions: Urine N1,N12-diacetylspermine is probably not a useful marker for urinary bladder cancer.
Key words: Acute coronary syndrome/Myocardial ischemia/Non-STEMI/Coronary by-pass/Laboratory markers of myocardial ischemia/CAD/GPBB/POCT/ELISABackground: Glycogen Phosphorylase BB (GPBB) is considered an early and specifi c marker of myocardial necrosis and ischemia. A POCT kit GPBB for diagnostic use has recently been approved.Aim: an evaluation of the correspondence of qualitative POCT GBPP measurements with ELISA test results. Material and methodology: 20 individuals with non-ST elevation myocardial infarction (non-STEMI) and 20 probands without acute coronary syndrome (ACS) were tested. GPBB (POCT, ELISA) in venous plasma (lithium-heparin) was assayed in all probands.Results: individuals with non-STEMI had signifi cantly higher GPBB ELISA values (32.3 vs. 6.1 μg/l; p < 0.01). GPBB sensitivity and specifi city for non-STEMI presence 6 hours after chest pain generation were 100 %. No proband was classifi ed in a diff erent subgroup with POCT of GPBB (positive/negative). GPBB POCT correlate with a non-STEMI diagnosis (χ 2 36.1; p < 0.01). Conclusion: GPBB POCT measurement is comparable with ELISA test results. GPBB analysis could expand the diagnostic palette in the fi rst hours after the onset of acute coronary syndrome.
Serum BTP measurement is sometimes believed to be an alternative marker of glomerular filtration rate (GFR) assessment. The aim of the present work was to investigate the correlation between creatinine, cystatin C, and BTP values in sera and to compare the diagnostic efficacy for serum BTP and cystatin C with the glomerular filtration rate estimate. 25 individuals were tested. GFR was estimated from creatinine clearance, serum cystatin C and BTP and urine α-1 microglobulin, albumin, GMT and creatinine were measured. BTP values correlated with cystatin C (r = 0.75; p < 0.01), creatinine (r = 0.73, p < 0.01), GFR (r = -0.46; p = 0.02), urine α-1-microglobulin (r = 0.66; p < 0.01). The diagnostic efficacy of BTP for reduced GFR was insufficient and the calculation of GFR with BTP was not included in the regression model.
Background: Clusterin is a glycoprotein which participates in a number of pathophysiological processes in the organism. Information about clusterin use in the diagnosis of nephropathy and the diff erential diagnosis of proteinuria has been published recently.Aim: Search for correlations between urinary clusterin concentration and other renal function markers. Evaluation of urinary clusterin measurement use in the diff erential diagnosis of nephropathy.Methods: Urea, creatinine, IgG, transferin, Na, K in serum and 24-hour collected urine were measured in a sample of 82 individuals. Cystatin C in sera was also measured as were GMT, α-1 microglobulin, albumin, total protein in urine. In all probands urinary clusterin was assayed (ELISA).Results: Urinary clusterin values correlated with urinary total protein concentrations (r = 0.28; p = 0.018), total protein/creatinine index (r = 0.26; p = 0.02). No correlation was found between urine clusterin concentration and glomerular fi ltration rate, age, urine GMT/creatinine, α-1-microglobulin, urine albumin and albumin/creatinine ratio or Na, K fractional excretions. We found no urinary clusterin diff erences by sex of probands.No evidence of any relationship between urine clusterin and presence of defect of renal function, number of risk factors (χ 2 = 16.0; DF = 15; p = 0.38), albumin/creatinine index (χ 2 = 0.76; DF = 3; p = 0,86), total protein/creatinine (χ 2 = 6.5; DF = 3; p = 0.09), GMT/creatinine (χ 2 = 2.3; DF = 3; p = 0.51), high urinary α-1-microglobulin (χ 2 = 4.1; DF = 3; p = 0.25) or decreased of GFR (χ 2 = 1.3; DF = 3; p = 0.74). Conclusions: A positive correlation exists between urinary clusterin and urinary total protein and total protein/ creatinine index. Urinary clusterin measurement with ELISA test does not off er any advantage over routinely used parameters for nephropathy diagnosis and the diff erential diagnosis of proteinuria type.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.